MoneyWorks4Me

Sandu Pharmaceutical - Quaterly Results

07 Feb 2026 Evaluate
The company's total revenue for the quarter ended December 2025 saw a slight change in the total revenue, having registered a total revenue of Rs. 187.61 millions.Handsome Net Profit growth of 75.68% reported above the corresponding previous quarter figure of Rs. 9.75 millions to Rs. 5.55 millions.Operating profit surged to 10.55 millions from the corresponding previous quarter of 10.15 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202512 202412 % Var 202512 202412 % Var 202503 202403 % Var
Sales 187.61 183.73 2.11 530.81 531.23 -0.08 671.92 672.81 -0.13
Other Income 0.14 0.25 -44.00 0.80 0.99 -19.19 1.68 4.21 -60.10
PBIDT 10.55 10.15 3.94 25.08 24.12 3.98 29.30 27.18 7.80
Interest 0.34 0.27 25.93 0.87 0.76 14.47 1.03 0.63 63.49
PBDT 10.21 9.88 3.34 24.21 23.36 3.64 28.27 26.55 6.48
Depreciation 1.66 1.90 -12.63 5.13 5.23 -1.91 6.71 5.83 15.09
PBT 8.55 7.98 7.14 19.08 18.13 5.24 21.56 20.72 4.05
TAX -1.20 2.43 -149.38 1.85 5.92 -68.75 6.07 6.12 -0.82
Deferred Tax -0.71 0.14 -607.14 -0.60 0.77 -177.92 0.18 0.25 -28.00
PAT 9.75 5.55 75.68 17.23 12.21 41.11 15.49 14.60 6.10
Equity 96.61 96.61 0.00 96.61 96.61 0.00 96.61 96.61 0.00
PBIDTM(%) 5.62 5.52 1.79 4.72 4.54 4.06 4.36 4.04 7.94
Peers
Company Name CMP
Sun Pharma. Inds. 1820.00
Dr. Reddys Labs. 1236.00
Cipla 1350.00
Lupin 2042.00
Zydus Lifesciences 1163.35
View more..